Literature DB >> 33462581

Validation of a Host Gene Expression Test for Bacterial/Viral Discrimination in Immunocompromised Hosts.

Rachael E Mahle1, Sunil Suchindran2, Ricardo Henao2,3, Julie M Steinbrink4, Thomas W Burke2, Micah T McClain2,4,5, Geoffrey S Ginsburg2, Christopher W Woods2,4,5, Ephraim L Tsalik2,4,6.   

Abstract

BACKGROUND: Host gene expression has emerged as a complementary strategy to pathogen detection tests for the discrimination of bacterial and viral infection. The impact of immunocompromise on host-response tests remains unknown. We evaluated a host-response test discriminating bacterial, viral, and noninfectious conditions in immunocompromised subjects.
METHODS: An 81-gene signature was measured using real-time-polymerase chain reaction in subjects with immunocompromise (chemotherapy, solid-organ transplant, immunomodulatory agents, AIDS) with bacterial infection, viral infection, or noninfectious illness. A regularized logistic regression model trained in immunocompetent subjects was used to estimate the likelihood of each class in immunocompromised subjects.
RESULTS: Accuracy in the 136-subject immunocompetent training cohort was 84.6% for bacterial versus nonbacterial discrimination and 80.8% for viral versus nonviral discrimination. Model validation in 134 immunocompromised subjects showed overall accuracy of 73.9% for bacterial infection (P = .04 relative to immunocompetent subjects) and 75.4% for viral infection (P = .30). A scheme reporting results by quartile improved test utility. The highest probability quartile ruled-in bacterial and viral infection with 91.4% and 84.0% specificity, respectively. The lowest probability quartile ruled-out infection with 90.1% and 96.4% sensitivity for bacterial and viral infection, respectively. Performance was independent of the type or number of immunocompromising conditions.
CONCLUSIONS: A host gene expression test discriminated bacterial, viral, and noninfectious etiologies at a lower overall accuracy in immunocompromised patients compared with immunocompetent patients, although this difference was only significant for bacterial infection classification. With modified interpretive criteria, a host-response strategy may offer clinically useful diagnostic information for patients with immunocompromise.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  gene expression profiling; host-pathogen interactions; immunocompromised host; molecular diagnostic techniques

Mesh:

Year:  2021        PMID: 33462581      PMCID: PMC8366815          DOI: 10.1093/cid/ciab043

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

1.  Comparing the Diagnostic Accuracy of Clinician Judgment to a Novel Host Response Diagnostic for Acute Respiratory Illness.

Authors:  Ian S Jaffe; Anja K Jaehne; Eugenia Quackenbush; Emily R Ko; Emanuel P Rivers; Micah T McClain; Geoffrey S Ginsburg; Christopher W Woods; Ephraim L Tsalik
Journal:  Open Forum Infect Dis       Date:  2021-11-10       Impact factor: 3.835

Review 2.  Antibiotic stewardship in the era of precision medicine.

Authors:  Richard R Watkins
Journal:  JAC Antimicrob Resist       Date:  2022-06-21

3.  Discriminating Bacterial and Viral Infection Using a Rapid Host Gene Expression Test.

Authors:  Ephraim L Tsalik; Ricardo Henao; Jesse L Montgomery; Jeff W Nawrocki; Mert Aydin; Emily C Lydon; Emily R Ko; Elizabeth Petzold; Bradly P Nicholson; Charles B Cairns; Seth W Glickman; Eugenia Quackenbush; Stephen F Kingsmore; Anja K Jaehne; Emanuel P Rivers; Raymond J Langley; Vance G Fowler; Micah T McClain; Robert J Crisp; Geoffrey S Ginsburg; Thomas W Burke; Andrew C Hemmert; Christopher W Woods
Journal:  Crit Care Med       Date:  2021-10-01       Impact factor: 9.296

4.  Prospective Validation of a Rapid Host Gene Expression Test to Discriminate Bacterial From Viral Respiratory Infection.

Authors:  Emily R Ko; Ricardo Henao; Katherine Frankey; Elizabeth A Petzold; Pamela D Isner; Anja K Jaehne; Nakia Allen; Jayna Gardner-Gray; Gina Hurst; Jacqueline Pflaum-Carlson; Namita Jayaprakash; Emanuel P Rivers; Henry Wang; Irma Ugalde; Siraj Amanullah; Laura Mercurio; Thomas H Chun; Larissa May; Robert W Hickey; Jacob E Lazarus; Shauna H Gunaratne; Daniel J Pallin; Guruprasad Jambaulikar; David S Huckins; Krow Ampofo; Ravi Jhaveri; Yunyun Jiang; Lauren Komarow; Scott R Evans; Geoffrey S Ginsburg; L Gayani Tillekeratne; Micah T McClain; Thomas W Burke; Christopher W Woods; Ephraim L Tsalik
Journal:  JAMA Netw Open       Date:  2022-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.